Pfizer beats earnings expectations in first report after criticism by activist investor

Taking stock of the drug industry, from the lab to the medicine chest

October 29, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT STAT+ | Pfizer beats earnings expectations in first report after criticism by activist investor Pfizer reported earnings for the first time since an activist investor took a $1 billion stake in the drug giant. By Matthew Herper STAT+ | Novartis raises profit guidance, pushes off myelofibrosis drug submission The company also said it could be a number of years before it can file for approval for an experimental myelofibrosis drug. By Andrew Joseph Opinion: I'm the director of the Center for Medicare. Here's how we executed the first round of drug price negotiation Medicare Director Meena Seshamani shares how the IRA drug price negotiations happened — and how the second round will be different. By Meena Seshamani Photo illustration: Christine Kao/STAT; Photos: Getty, Adobe, Sam Ogden STAT+ | Dreams of cancer vaccines are becoming more real. Here are 9 scientists making it happen  STAT profile series looks at movers and shakers in various fields: Here are nine researchers on the cutting edge of cancer vaccine research. By Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser